Oncotelic Therapeutics IncOTCQB:OTLC
- LAST PRICE0.0420
- TODAY'S CHANGE (%)0.0012 (2.9412%)
- Bid / Lots0.0360/ 100
- Ask / Lots0.0440/ 100
- Open / Previous Close0.0400 / 0.0408
- Day Range
- 52 Week Range
- Volume22,308
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OTLC |
|---|---|---|
| 12:16 ET | 500 | 0.04 |
| 12:56 ET | 15000 | 0.038 |
| 01:39 ET | 500 | 0.0361 |
| 02:31 ET | 500 | 0.03787 |
| 02:40 ET | 355 | 0.0361 |
| 03:32 ET | 2450 | 0.0361 |
| 03:56 ET | 3000 | 0.042 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Oncotelic Therapeutics Inc | 16.3M | -2.1x | --- |
Protext Mobility Inc | 15.8M | 0.0x | --- |
Curative Biotechnology Inc | 15.8M | -2.7x | --- |
ABVC Biopharma Inc | 16.8M | -0.6x | --- |
Cardio Diagnostics Holdings Inc | 15.6M | -0.9x | --- |
Nascent Biotech Inc | 17.0M | -6.8x | --- |
Company Information
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. The Company’s pipeline includes OT-101, CA4P and Oxi4503. OT-101 is antisense against TGF-2 for the treatment of solid tumors with focus on brain cancer in adults and diffuse intrinsic pontine glioma (DIPG) in children. OT-101 is antisense against TGF-2 for the treatment of various viruses, including the SARS and the COVID-19, on its own and in conjunction with other compounds. CA4P is a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma. Oxi4503 is VDA for the treatment of liquid tumors with a focus on childhood leukemia.
Contact Information
- Headquarters
- 29397 Agoura Road Suite 107AGOURA HILLS, CA, United States 91301
- Phone
- 650-635-7000
- Fax
- 650-635-7001
Executives
- Chairman of the Board, Chief Executive Officer
- Vuong Trieu
- Chief Financial Officer
- Amit Shah
- Chief Medical Officer - Translation Medicine, Director
- Anthony Maida
- Chief Medical Officer, Chief Regulatory Officer (Consultant)
- Seymour Fein
- Chief Business Officer
- Saran Saund
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.3M |
|---|---|
Revenue (TTM) | $70.0K |
Shares Outstanding | 399.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.02 |
EPS | $-0.02 |
Book Value | $0.03 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | 233.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -10,083.07% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
